Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.

Shuchen ChenHonglin ZhuMeizi JinHongling YuanZhenzhen LiuJielin LiXiang ZhangLihui MengTing LiYuzhu DiaoHong GaoChengyu HongXinjiang ZhuJian ZhengFei LiYanling NiuTonghui Ma Xiaoling Li

Published in: Cancer medicine (2022)

Taken together, this study reveals the molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and provides a theoretical basis for IDH-directed treatment. The potential of IDH mutations as response markers for targeted therapy warrants further investigation.

Keyphrases

end stage renal disease
ejection fraction
small cell lung cancer
low grade
newly diagnosed
prognostic factors
patient reported outcomes
single molecule
patient reported
combination therapy